Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIDENT-1 Japan study of repotrectinib in ALK/ROS1/NTRK-rearranged advanced solid tumors
jRCT2011210009Phase 2Active, not recruiting
- Sponsor
- Turning Point Therapeutics, Inc.
- Start
- May 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of repotrectinib in Nonhematologic neoplasms and non-small cell lung cancer (NSCLC), sponsored by Turning Point Therapeutics, Inc. Primary endpoints: Safety, Tolerability and 2 more. Started May 2021; status: active, not recruiting.
02
Drugs
repotrectinib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2011210009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210009.